Cohort B patient baseline characteristics (n=10) | |
Mean age, years | 68.5 |
Performance status: 0 no (%) | 6 (60) |
Sex—male no (%) | 5 (50) |
M-stage—no (%) | |
M1a | 4 (40) |
M1b | 4 (40) |
M1c | 2 (20) |
Metastatic sites (no) | |
1 | 3 (30) |
2–3 | 5 (50) |
>3 | 2 (20) |
Patients with liver metastases | 1 (10) |
Lactate dehydrogenaselevels | |
≤Upper limit of normal | 9 (90) |
>Upper limit of normal | 1 (10) |
PD-L1 (%) | |
<1% | 5 (50) |
>1% | 3 (30) |
Unknown | 2 (20) |
BRAF-status (%) | |
Mutant | 0 (0) |
Wild-type | 10 (100) |
Previous systemic treatment | |
Ipilimumab | 2 (20) |
Pembrolizumab | 7 (70) |
Adjuvant nivolumab | 3 (30) |
Temozolomide | 1 (10) |
IL-2 | 1 (10) |